Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
deals
11
×
life sciences
national blog main
national top stories
11
×
biotech
boston top stories
san francisco blog main
clinical trials
san francisco top stories
boston
startups
alnylam pharmaceuticals
fda
new york blog main
new york top stories
sanofi
hepatitis b
investing
ipo
rna interference
roche
vc
alexion pharmaceuticals
amgen
boehringer ingelheim
cancer
crispr
eli lilly
genentech
glaxosmithkline
indiana blog main
indiana top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco
sickle cell disease
What
medicines
11
×
drug
new
deal
disease
research
years
adds
ago
bio
biotech
cancer
dicerna
diseases
fda
gene
hepatitis
ipo
pharma
roche
startup
targets
team
therapeutics
abandoning
acquire
acquisitions
address
agreed
aiming
aims
alliance
allosteric
ambys
announced
approach
approval
areas
baggage
based
Language
unset
Current search:
deals
×
" national top stories "
×
medicines
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?